Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab as consolidation therapy in recurrent head and neck cancer
NCT04188951Phase 1Completed
- Sponsor
- Henry Ford Health
- Start
- Oct 2019
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Henry Ford Health. Primary endpoint: Rate of recurrence at 1 year. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04188951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188951.